Tolerance to morphine at the mu-opioid receptor differentially induced by cAMP-dependent protein kinase activation and morphine

Eur J Pharmacol. 2000 Feb 18;389(2-3):165-71. doi: 10.1016/s0014-2999(99)00881-x.

Abstract

Human neuroblastoma SH-SY5Y cells express endogenous mu-opioid receptor and develop cellular tolerance to morphine after prolonged (>/=4 h) treatment with morphine. Treatment with forskolin (25 microM, 12 h), an adenylyl cyclase activator, also desensitized mu-opioid receptor response to morphine (10 microM) by 38% (P<0. 001), which was reversed by the cyclic AMP (cAMP) dependent kinase inhibitor N-(2-aminoethyl)-5-isoquinolinesulfonamide (H8) (100 microM). Treatment with both morphine and forskolin appeared to cause an additive effect in desensitizing mu-opioid receptor. In mu-opioid receptor stably transfected human embryonic kidney 293 (HEK-mu) cells, morphine treatment produced cAMP upregulation, yet failed to induce mu-opioid receptor tolerance. However, treatment with forskolin (25 microM) or 8-bromo-cAMP (1mM) led to profound mu-opioid receptor tolerance, which was reversed by H8. These results demonstrate that cAMP-dependent kinase activation causes mu-opioid receptor tolerance. However, morphine-induced mu-opioid receptor tolerance in SH-SY5Y cells is not mediated by cAMP-dependent kinase activation. In addition, our results indicate that cAMP-upregulation does not necessarily lead to mu-opioid receptor tolerance.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Colforsin / pharmacology
  • Cyclic AMP / physiology
  • Cyclic AMP-Dependent Protein Kinases / physiology*
  • Drug Tolerance
  • Enzyme Activation
  • Humans
  • Morphine / pharmacology*
  • Narcotics / pharmacology*
  • Phosphorylation
  • Receptors, Opioid, mu / drug effects*
  • Tumor Cells, Cultured

Substances

  • Narcotics
  • Receptors, Opioid, mu
  • Colforsin
  • Morphine
  • Cyclic AMP
  • Cyclic AMP-Dependent Protein Kinases